CN102353770A - 胱氨酸蛋白酶抑制剂c检测试剂盒 - Google Patents
胱氨酸蛋白酶抑制剂c检测试剂盒 Download PDFInfo
- Publication number
- CN102353770A CN102353770A CN2011101511250A CN201110151125A CN102353770A CN 102353770 A CN102353770 A CN 102353770A CN 2011101511250 A CN2011101511250 A CN 2011101511250A CN 201110151125 A CN201110151125 A CN 201110151125A CN 102353770 A CN102353770 A CN 102353770A
- Authority
- CN
- China
- Prior art keywords
- proteinase inhibitor
- antibody
- detection kit
- cystine
- latex particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title claims abstract description 51
- 229960003067 cystine Drugs 0.000 title claims abstract description 50
- 238000001514 detection method Methods 0.000 title claims abstract description 30
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 title claims abstract 20
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title abstract 3
- 239000004816 latex Substances 0.000 claims abstract description 65
- 229920000126 latex Polymers 0.000 claims abstract description 65
- 239000002245 particle Substances 0.000 claims abstract description 46
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 28
- 239000004793 Polystyrene Substances 0.000 claims abstract description 10
- 229920002223 polystyrene Polymers 0.000 claims abstract description 10
- 239000000872 buffer Substances 0.000 claims abstract description 7
- 238000013016 damping Methods 0.000 claims description 20
- 239000012530 fluid Substances 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000010168 coupling process Methods 0.000 claims description 11
- 230000008878 coupling Effects 0.000 claims description 9
- 238000005859 coupling reaction Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims description 4
- 229910000071 diazene Inorganic materials 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- ADAMEOZKZQRNKP-UHFFFAOYSA-N n'-propylmethanediimine Chemical compound CCCN=C=N ADAMEOZKZQRNKP-UHFFFAOYSA-N 0.000 claims description 4
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 claims description 2
- ZHUXMBYIONRQQX-UHFFFAOYSA-N hydroxidodioxidocarbon(.) Chemical compound [O]C(O)=O ZHUXMBYIONRQQX-UHFFFAOYSA-N 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 31
- 238000000034 method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000012412 chemical coupling Methods 0.000 description 5
- 230000024924 glomerular filtration Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000004879 turbidimetry Methods 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001132 ultrasonic dispersion Methods 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
CYS-C(mg/L) | 测定次数 | 均值 | 2.6SD | M+2.6SD | M-2.6SD |
0 | 10 | 0.02 | 0.031 | 0.05 | -0.02 |
0.04 | 10 | 0.05 | 0.044 | 0.10 | 0.01 |
0.08 | 10 | 0.10 | 0.031 | 0.13 | 0.07 |
0.12 | 10 | 0.15 | 0.058 | 0.21 | 0.10 |
0.16 | 10 | 0.19 | 0.044 | 0.23 | 0.14 |
0.20 | 10 | 0.22 | 0.032 | 0.25 | 0.19 |
CYS-C理论值(mg/L) | CYS-C实际值(mg/L) | |
1 | 0 | 0 |
2 | 1.5 | 1.51 |
3 | 2.5 | 2.55 |
4 | 3.5 | 3.52 |
5 | 4.5 | 4.58 |
6 | 5.5 | 5.57 |
7 | 6.5 | 6.54 |
8 | 7.5 | 7.43 |
9 | 8.5 | 8.02 |
10 | 9.5 | 8.22 |
样品1 | 样品2 | |
测定次数 | 20 | 20 |
平均值(mg/L) | 0.715 | 5.659 |
最小值(mg/L) | 0.700 | 5.42 |
最大值(mg/L) | 0.730 | 5.78 |
标准差(SD) | 0.0097 | 0.0920 |
变异系数(CV%) | 1.36 | 1.62 |
项目 | 0月 | 4月 | 8月 | 12月 | 14月 |
试剂空白吸光度A0 | 0.7871 | 0.7780 | 0.7809 | 0.7951 | 0.7885 |
样本测得值 | 0.821 | 0.830 | 0.835 | 0.840 | 0.841 |
批内CV(%) | 1.30 | 1.32 | 1.25 | 1.42 | 1.57 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110151125 CN102353770B (zh) | 2011-06-03 | 2011-06-03 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110151125 CN102353770B (zh) | 2011-06-03 | 2011-06-03 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102353770A true CN102353770A (zh) | 2012-02-15 |
CN102353770B CN102353770B (zh) | 2013-11-06 |
Family
ID=45577372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110151125 Active CN102353770B (zh) | 2011-06-03 | 2011-06-03 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102353770B (zh) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102590497A (zh) * | 2012-01-13 | 2012-07-18 | 宁波美康生物科技股份有限公司 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
CN102636653A (zh) * | 2012-04-19 | 2012-08-15 | 上海蓝怡科技有限公司 | 复合胶乳粒子包被胱抑素c检测试剂盒 |
CN102662059A (zh) * | 2012-05-11 | 2012-09-12 | 北京美康生物技术研究中心 | 一种用于测定幽门螺杆菌抗体的胶乳增强免疫比浊试剂盒及其制备方法和应用 |
CN102749458A (zh) * | 2012-07-27 | 2012-10-24 | 北京恩济和生物科技有限公司 | 一种胱抑素c检测试剂盒及其制备方法 |
CN102879569A (zh) * | 2012-09-18 | 2013-01-16 | 苏州照康生物技术有限公司 | 检测半胱氨酸蛋白酶抑制剂c的免疫比浊试剂盒及其制备方法 |
CN103175964A (zh) * | 2013-02-21 | 2013-06-26 | 武汉华美生物工程有限公司 | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 |
CN104049084A (zh) * | 2013-03-11 | 2014-09-17 | 南京澳林生物科技有限公司 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
CN105137082A (zh) * | 2015-07-31 | 2015-12-09 | 柏荣诊断产品(上海)有限公司 | 一种双试剂糖化血红蛋白检测试剂盒 |
CN105372434A (zh) * | 2015-08-13 | 2016-03-02 | 浙江卓运生物科技有限公司 | 人血清淀粉样蛋白a检测试剂盒 |
CN105699655A (zh) * | 2016-01-26 | 2016-06-22 | 宁波天康生物科技有限公司 | α1-微球蛋白检测试剂盒 |
CN105717292A (zh) * | 2016-02-01 | 2016-06-29 | 杭州惟新生物技术有限公司 | 脂蛋白磷脂酶a2检测试剂盒 |
CN108169482A (zh) * | 2017-12-20 | 2018-06-15 | 河南联博生物科技有限公司 | 一种胶乳增强免疫比浊法定量检测克伦特罗的试剂 |
CN109613264A (zh) * | 2018-12-29 | 2019-04-12 | 中拓生物有限公司 | 一种灵敏度高的载脂蛋白c2测定试剂盒 |
CN109613265A (zh) * | 2018-12-29 | 2019-04-12 | 中拓生物有限公司 | 一种用胶乳免疫比浊法测定载脂蛋白c3的试剂盒 |
CN109738644A (zh) * | 2018-12-24 | 2019-05-10 | 恩碧乐(杭州)生物科技有限公司 | 一种抗穆勒氏管激素免疫比浊定量检测试剂 |
CN110412292A (zh) * | 2019-07-31 | 2019-11-05 | 宁波海壹生物科技有限公司 | 一种简单有效去除样本中类风湿因子干扰的胱抑素c测定试剂盒 |
CN110501493A (zh) * | 2019-08-28 | 2019-11-26 | 郑州安图生物工程股份有限公司 | 一种人副流感病毒3型IgM抗体的检测试剂盒 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101241128A (zh) * | 2008-03-18 | 2008-08-13 | 上海大学 | 黄曲霉毒素免疫亲和柱的制备方法 |
WO2008142057A1 (en) * | 2007-05-21 | 2008-11-27 | Gentian As | Turbidimetric immunoassay for assessing human cystatin c |
CN101377492A (zh) * | 2007-08-29 | 2009-03-04 | 北京九强生物技术有限公司 | 胱抑素c测定试剂盒 |
CN101413001A (zh) * | 2008-11-28 | 2009-04-22 | 四川省迈克科技有限责任公司 | 重组人胱抑素c基因及其表达与应用 |
CN101680891A (zh) * | 2007-11-21 | 2010-03-24 | 爱科来株式会社 | 测定试剂、使用其的免疫比浊法和待测物分析用具 |
CN102007412A (zh) * | 2008-05-09 | 2011-04-06 | 爱科来株式会社 | 不溶性载体颗粒的制造方法、不溶性载体颗粒、测定试剂、待测物分析用具和免疫比浊法 |
-
2011
- 2011-06-03 CN CN 201110151125 patent/CN102353770B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008142057A1 (en) * | 2007-05-21 | 2008-11-27 | Gentian As | Turbidimetric immunoassay for assessing human cystatin c |
CN101377492A (zh) * | 2007-08-29 | 2009-03-04 | 北京九强生物技术有限公司 | 胱抑素c测定试剂盒 |
CN101680891A (zh) * | 2007-11-21 | 2010-03-24 | 爱科来株式会社 | 测定试剂、使用其的免疫比浊法和待测物分析用具 |
CN101241128A (zh) * | 2008-03-18 | 2008-08-13 | 上海大学 | 黄曲霉毒素免疫亲和柱的制备方法 |
CN102007412A (zh) * | 2008-05-09 | 2011-04-06 | 爱科来株式会社 | 不溶性载体颗粒的制造方法、不溶性载体颗粒、测定试剂、待测物分析用具和免疫比浊法 |
CN101413001A (zh) * | 2008-11-28 | 2009-04-22 | 四川省迈克科技有限责任公司 | 重组人胱抑素c基因及其表达与应用 |
Non-Patent Citations (3)
Title |
---|
《Journal of Immunological Methods》 19781231 G. QUASH et al THE PREPARATION OF LATEX PARTICLES WITH COVALENTLY BOUND POLYAMINES, IgG AND MEASLES AGGLUTININS AND THEIR USE IN VISUAL AGGLUTINATION TESTS 第2卷, 第1-2期 * |
G. QUASH ET AL: "THE PREPARATION OF LATEX PARTICLES WITH COVALENTLY BOUND POLYAMINES, IgG AND MEASLES AGGLUTININS AND THEIR USE IN VISUAL AGGLUTINATION TESTS", 《JOURNAL OF IMMUNOLOGICAL METHODS》, vol. 2, no. 12, 31 December 1978 (1978-12-31) * |
VADIM V SHMANAI ET AL: "Oriented antibody immobilization to polystyrene macrocarriers for immunoassay modified with hydrazide derivatives of poly(meth)acrylic acid", 《BMC BIOTECHNOLOGY》, vol. 1, no. 4, 30 August 2001 (2001-08-30) * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102590497B (zh) * | 2012-01-13 | 2014-01-01 | 宁波美康生物科技股份有限公司 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
CN102590497A (zh) * | 2012-01-13 | 2012-07-18 | 宁波美康生物科技股份有限公司 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
CN102636653A (zh) * | 2012-04-19 | 2012-08-15 | 上海蓝怡科技有限公司 | 复合胶乳粒子包被胱抑素c检测试剂盒 |
CN102662059A (zh) * | 2012-05-11 | 2012-09-12 | 北京美康生物技术研究中心 | 一种用于测定幽门螺杆菌抗体的胶乳增强免疫比浊试剂盒及其制备方法和应用 |
CN102749458A (zh) * | 2012-07-27 | 2012-10-24 | 北京恩济和生物科技有限公司 | 一种胱抑素c检测试剂盒及其制备方法 |
CN102879569A (zh) * | 2012-09-18 | 2013-01-16 | 苏州照康生物技术有限公司 | 检测半胱氨酸蛋白酶抑制剂c的免疫比浊试剂盒及其制备方法 |
CN103175964B (zh) * | 2013-02-21 | 2015-08-26 | 武汉华美生物工程有限公司 | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 |
CN103175964A (zh) * | 2013-02-21 | 2013-06-26 | 武汉华美生物工程有限公司 | 神经元特异性烯醇化酶含量检测试剂盒及其制备方法 |
CN104049084A (zh) * | 2013-03-11 | 2014-09-17 | 南京澳林生物科技有限公司 | 胱氨酸蛋白酶抑制剂c检测试剂盒 |
CN105137082A (zh) * | 2015-07-31 | 2015-12-09 | 柏荣诊断产品(上海)有限公司 | 一种双试剂糖化血红蛋白检测试剂盒 |
CN105372434A (zh) * | 2015-08-13 | 2016-03-02 | 浙江卓运生物科技有限公司 | 人血清淀粉样蛋白a检测试剂盒 |
CN105699655A (zh) * | 2016-01-26 | 2016-06-22 | 宁波天康生物科技有限公司 | α1-微球蛋白检测试剂盒 |
CN105717292A (zh) * | 2016-02-01 | 2016-06-29 | 杭州惟新生物技术有限公司 | 脂蛋白磷脂酶a2检测试剂盒 |
CN108169482A (zh) * | 2017-12-20 | 2018-06-15 | 河南联博生物科技有限公司 | 一种胶乳增强免疫比浊法定量检测克伦特罗的试剂 |
CN109738644A (zh) * | 2018-12-24 | 2019-05-10 | 恩碧乐(杭州)生物科技有限公司 | 一种抗穆勒氏管激素免疫比浊定量检测试剂 |
CN109613264A (zh) * | 2018-12-29 | 2019-04-12 | 中拓生物有限公司 | 一种灵敏度高的载脂蛋白c2测定试剂盒 |
CN109613265A (zh) * | 2018-12-29 | 2019-04-12 | 中拓生物有限公司 | 一种用胶乳免疫比浊法测定载脂蛋白c3的试剂盒 |
CN110412292A (zh) * | 2019-07-31 | 2019-11-05 | 宁波海壹生物科技有限公司 | 一种简单有效去除样本中类风湿因子干扰的胱抑素c测定试剂盒 |
CN110501493A (zh) * | 2019-08-28 | 2019-11-26 | 郑州安图生物工程股份有限公司 | 一种人副流感病毒3型IgM抗体的检测试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN102353770B (zh) | 2013-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102353770B (zh) | 胱氨酸蛋白酶抑制剂c检测试剂盒 | |
CN102590526B (zh) | β2-微球蛋白检测试剂盒 | |
CN102628867B (zh) | 双抗体胶乳增强视黄醇结合蛋白检测试剂盒 | |
CN101769932B (zh) | 全量程c反应蛋白检测试剂盒 | |
CN102590497B (zh) | 胱氨酸蛋白酶抑制剂c检测试剂盒 | |
CN102628865B (zh) | 检测肌红蛋白含量的胶乳增强免疫比浊试剂盒 | |
CN105372434A (zh) | 人血清淀粉样蛋白a检测试剂盒 | |
CN103149370B (zh) | 脂蛋白(a)检测试剂盒 | |
CN103823070A (zh) | 一种高灵敏度的胱抑素c测定试剂盒 | |
CN102565419B (zh) | 肌红蛋白检测试剂盒 | |
CN102539784B (zh) | 心肌肌钙蛋白i检测试剂盒 | |
CN103645323B (zh) | 一种胱抑素c检测试剂盒及其制备方法 | |
CN106932589A (zh) | 测定人体血清视黄醇结合蛋白含量的试剂盒及其制备方法 | |
CN108226531A (zh) | 一种β2-微球蛋白检测试剂盒 | |
CN105486875A (zh) | 视黄醇结合蛋白检测试剂盒 | |
CN104614528A (zh) | 一种线性范围更宽的视黄醇结合蛋白测定试剂盒 | |
CN105717292A (zh) | 脂蛋白磷脂酶a2检测试剂盒 | |
CN104535770A (zh) | 一种复合抗体的肌红蛋白测定试剂盒 | |
CN105974106B (zh) | 11-脱氢-血栓素b2测定试剂盒及其用途 | |
CN110007074A (zh) | 用于检测c反应蛋白的试剂盒、其制备方法及用途 | |
CN101819208B (zh) | 一种纳米微球免疫比浊法检测脑钠肽试剂盒 | |
CN105675891A (zh) | 脂蛋白a(Lp(a))测定试剂盒 | |
CN106370860A (zh) | 血清免疫球蛋白e胶体金层析定量检测试剂盒及试纸条 | |
CN106771152A (zh) | 一种快速检测钙卫蛋白的试剂盒 | |
CN105606822A (zh) | β2-微球蛋白检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 315104 Zhejiang city of Ningbo province Yinzhou District Qiming Road No. 299 Applicant after: NINGBO MEDICAL SYSTEM BIOTECHNOLOGY Co.,Ltd. Address before: 315104 Zhejiang city of Ningbo province Yinzhou District Qiming Road No. 299 Applicant before: Ningbo Medical System Biotechnology Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: MEIKANG BIOTECH CO., LTD., NINGBO TO: NINGBO MEDICAL SYSTEM BIOTECHNOLOGY CO., LTD. |
|
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zou Bingde Inventor before: Zou Bingde Inventor before: Xia Jiayin |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZOU BINGDE XIA JIAYIN TO: ZOU BINGDE |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 315104 Zhejiang city of Ningbo province Yinzhou District Qiming Road No. 299 Patentee after: MEDICAL SYSTEM BIOTECHNOLOGY Co.,Ltd. Address before: 315104 Zhejiang city of Ningbo province Yinzhou District Qiming Road No. 299 Patentee before: NINGBO MEDICAL SYSTEM BIOTECHNOLOGY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120215 Assignee: Ningbo Shengyuan Biotechnology Co., Ltd. Assignor: MEDICAL SYSTEM BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2022330000361 Denomination of invention: Cystatin C Detection Kit Granted publication date: 20131106 License type: Common License Record date: 20220809 |